Zivo Bioscience, Inc. (OTCQB: ZIVO) has announced significant changes in its leadership and strategic direction as part of its ongoing cost-cutting measures. On March 26, 2026, William A. Sullivan, the Interim Chief Financial Officer, announced his resignation effective March 30, 2026. Concurrently, Alison A. Cornell resigned from the Board of Directors and all committees, effective immediately. Both resignations are linked to the company's decision to deregister its securities and cease public reporting, a move aimed at reducing financial burdens associated with SEC compliance. The company plans to file a Form 15 with the SEC to suspend its reporting obligations, which will relieve it from the necessity of filing certain reports, including Forms 10-K, 10-Q, and 8-K. This decision is expected to allow Zivo to redirect resources towards its core business operations and strategic objectives, potentially enhancing long-term value for shareholders. The company remains committed to advancing its animal health and nutrition segments, with expectations of generating revenue from its AgTech product line in the near future. Zivo's management believes that the resources freed from public company compliance obligations will better support its business objectives and shareholder value creation.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.